Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC)

Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC)

Sponsors and Collaborators
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Pfizer
GlaxoSmithKline

Contact
Maryellen Sun, MD
617-754-2559
msun@bidmc.harvard.edu

Principal Investigator
Maryellen Sun, MD, Beth Israel Deaconess Medical Center

ClinicalTrials.gov Identifier
NCT00749320

Loading links....
You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters